7th Dermatology Drug Development Summit

The Dermatology Drug Development Summit returns for its 7th year as the largest industry focused summit dedicated to advancing treatment options across Atopic Dermatitis, Alopecia Areata, Hidradenitis suppurativa, Prurigo Nodularis and Vitiligo to name a few.

From improving the safety profile of JAK inhibitors to opening the doors to maintenance therapies and cracking the first approved therapies in rare dermatological diseases, these strategic and progressive conversations are not ones to be missed.

This summit provides optimal opportunity to meet with 120+ key opinion leaders from LEO Pharma, AbbVie, Janssen, Sanofi, Almirall, GSK, BMS, Incyte, Dermavant and more to accelerate dermatology pipelines and work towards achieving durable therapies following the success in attaining remittive therapy in Psoriasis.

Brochure https://go.evvnt.com/1818122-0?pid=10018
Tickets https://go.evvnt.com/1818122-1?pid=10018

Prices:
Conference Only - Drug Developer Rate USD 2999.00
Conference + Seminar Day - Drug Developer Rate USD 4946.00
Conference Only - Service Provider Rate USD 3799.00
Conference + Seminar Day - Service Provider Rate USD 6064.00

Speakers: Carine Blanchard, Chief Scientific Officer, Aldena Therapeutics, Dirk Brockstedt, Chief Scientific Officer, RAPT Therapeutics, Eric Meldrum, Chief Scientific Officer & Interim Chief Executive Officer, Citryll, Esther Garcia, Gil Director, Global Clinical Development, Almirall, Fauad Hasan, Chief Executive Officer, Ornovi, Ferda Cevikbas, Executive Director & Head of Translational Sciences, ASLAN Pharmaceuticals, Harald Schnidar, Chief Executive Officer & President, Scarletred Holding Gmbh, Heike Keilhack, Chief Scientific Officer, Ribon Therapeutics, Humberto Antunes, Partner, Gore Range Capital & Former Chief Executive Officer, Galderma, Iain Stuart, Chief Scientific Officer, Vyne Corp., Janine Fournier, Senior Director, Medical Value and Access, Dermavant, Jeremy Sokolove, Senior Vice President, Clinical Pharmacology & Experimental Medicine, GlaxoSmithKline Plc, Johan Lund, Chief Scientific Officer, AQILION AB, John Armstrong, President, JAV & Former Head of Discovery & Global Strategic Programs, Galderma, John Harris, Professor & Chair, Department of Dermatology, University of Massachusetts Medical School, Karen McGuire, Chief Executive Officer, BioMendics, Kelly Pike, Senior Director, Head of Translational Sciences, Ventus Therapeutics, Kim Kjøller, Chief Executive Officer, UNION therapeutics A/S, Kimberly McHale, Senior Director, Nonclinical Science, Dermavant, Kumar Krishnaswamy, Scientific Director, Abbvie, Lars Rosendal, Vice President, Global Clinical Operations, LEO Pharma, Lloyd Miller, Vice President, Immunodermatology Disease Area Leader, Janssen Pharmaceuticals, Luis F Santamaria-Babí, Professor, University of Barcelona, Meena Arora, Head of Medical Affairs, Amryt Pharma, Michael Herbig, Chief Executive Officer, RaDes GmbH, Mudgal Kothekar, Vice President, Clinical Development, Sun Pharma Advanced Research Co. Ltd., Ofer Toledano, Vice President, Research & Development, Sol Gel Technologies, Orna Goren, Product Cluster Leader, Clexio Biosciences, Par Nijhawan, Chief Executive Officer & Founder, ​​Edesa Biotech Inc., Paul Rowe, Vice President & Head Of Global Medical Immunology, Sanofi, Paul Smith, Senior Vice President, Biology, Recludix Pharma, Prista Charuworn, Executive Director, Inflammation & Global Development Lead, Amgen Inc., Rahul Mehta, Vice President, Research & Development, Abbvie, Rob Ortmann, Vice President, Clinical Development, Aclaris Therapeutics Inc., Scott Plevy, Executive Vice President & Therapeutic Head of Gastroenterology, Protagonist Therapeutics Inc., Subhashish Banerjee, Vice President and Disease Area Head, Rheumatology and Dermatology, Bristol Myers Squibb, Susan Smith, Senior Director, Translational Science, Incyte Corporation